Background Studies

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) has …


Boehringer Ingelheim ed Eli Lilly and Company (NYSE: LLY) hanno annunciato oggi …

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today that both randomized controlled trials of the EASE Phase III program evaluating empagliflozin in combination with insulin therapy, in adults with type 1 diabetes, have reached their primary endpoint.


Tags
Close